COLO B Coloplast A/S Class B

Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference call on 6 May 2025 at 11.00am CEST

Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference call on 6 May 2025 at 11.00am CEST

Tuesday, 6 May 2025 at 11.00 - 12.00am CEST

In connection with the publication of Coloplast’s interim financial results for H1 2024/25, to be released same day around 07.30am CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.

The webcast of the conference call will be available during and after the event.



Coloplast will be represented by:

Kristian Villumsen - President & CEO

Anders Lonning-Skovgaard - Executive Vice President, CFO

Aleksandra Dimovska - Vice President, Investor Relations

Simone Dyrby Helvind - Senior Manager, Investor Relations



Webcast

For participants who do not wish to actively participate in the Q&A session, please access the conference call as a webcast via the link below:



Dial-in details

To actively participate in the Q&A session, please sign up ahead of the conference call on the link below to receive an email with dial-in details.

 

For more information, please contact:

Aleksandra Dimovska - Vice President, Investor Relations

Tel.: / direct: . E-mail:

Simone Dyrby Helvind - Senior Manager, Investor Relations

Tel.: / direct: . E-mail:

Julie Sommer Müggler - Coordinator & PA, Investor Relations

Tel.: / direct: . E-mail: 

 

Coloplast will be available on individual phone lines after the conference call for further questions.

Attachment



EN
15/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

Coloplast AS: 1 director

A director at Coloplast AS bought 18,450 shares at 650.500DKK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående p...

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående personers handel med Coloplast-aktier Se venligst vedlagte pdf.   Vedhæftet fil

 PRESS RELEASE

Coloplast A/S - Trading in Coloplast shares by board members, executiv...

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons Please see enclosed pdf.   Attachment

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
 PRESS RELEASE

Coloplast A/S - Selskabsmeddelelse nr. 04/2025 - Regnskabsmeddelelse, ...

Coloplast A/S - Selskabsmeddelelse nr. 04/2025 - Regnskabsmeddelelse, 1. halvår 2024/25 Delårsrapport, første halvår 2024/25  1. oktober 2024 – 31. marts 2025  Coloplast leverede 6% organisk vækst i 2. kvartal, påvirket af produkttilbagekaldelsen i Urologi og et svagt kvartal i Stomi. Overskudsgraden1 i 2. kvartal holdt sig stabil på 27%. Den rapporterede omsætning målt i danske kroner steg 5%, påvirket af frasalget af hudplejeforretningen.  Den organiske vækst pr. forretningsområde var 4% i Stomi, 8% i Kontinens, 7% i Stemme og Respiratorisk Pleje, 10% i Avanceret Sårpleje og -1% i Urol...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch